ContractJanuary 12th, 2021FiledJanuary 12th, 2021Sarepta Therapeutics and Selecta Biosciences Enter Into Research License and Option Agreement for Selecta’s ImmTOR Immune Tolerance Platform in Neuromuscular Diseases
Sarepta Therapeutics and Selecta Biosciences Enter Into Research License and Option Agreement for Selecta’s ImmTOR Immune Tolerance Platform in Neuromuscular Diseases